Drugs / TEMTOKIBART
TEMTOKIBART
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05099133 | Nov 2021 → Jun 2022 | atopic eczema | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03514511 | May 2018 → Mar 2021 | atopic eczema | LEO Pharma | Completed | No outcome recorded |
| Phase 23 trials · 2 met primary | ||||||
| Phase 2 | NCT05923099 | Sep 2023 → Dec 2024 | atopic eczema | LEO Pharma | Completed | Met primary |
| Phase 2 | NCT05470114 | May 2022 → Jun 2023 | atopic eczema | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT04922021 | Jul 2021 → Jun 2022 | atopic eczema | LEO Pharma | Completed | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEMTOKIBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314778 ↗ |
| Known as | clone 230C9 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314778 ↗ |
| Known as | IL-22R | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314778 ↗ |
| Known as | LEO 138559 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05099133 ↗ |
| Known as | LEO 138559 is also called "temtokibart" | “LEO 138559 is also called "temtokibart"” NCT05923099 ↗ |
| Modality | Protein / enzyme biologic | “LEO 138559 is an antibody given by subcutaneous injection.” NCT05470114 ↗ |
| Route | Subcutaneous | “given by injection just under the skin” NCT04922021 ↗ |